PRAX-628, a Nav blocker with improved potency and tolerability compared to standard of care
Dec. 9, 2022
Researchers from Praxis Precision Medicines Inc. presented the discovery and preclinical evaluation of a novel voltage-gated sodium channel (Nav) blocker, PRAX-628, being developed as a potential antiepileptic drug candidate.
